| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | President, Head of R&D | Stock Options (Right to buy) | 110,500 | $1,618,825 | $14.65 | 05 Feb 2025 | Direct |
| Syndax Pharmaceuticals Inc | President, Head of R&D | Common Stock | 85,095 | $1,319,313 | $15.50 | 10 Feb 2025 | Direct |
| Foghorn Therapeutics Inc. | Director | Stock Options (Right to buy) | 50,000 | $208,000 | $4.16 | 01 May 2025 | Direct |
| Zymeworks Inc. | Director | Stock Option (Right to Buy) | 31,000 | 10 Dec 2024 | Direct | ||
| Zymeworks Inc. | Director | No securities are beneficially owned | 0 | 02 Apr 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | 01 May 2025 | 1 | +$208,000 | 4 | Director | 02 May 2025, 16:04 |
| FHTX | Foghorn Therapeutics Inc. | 01 May 2025 | 0 | $0 | 3 | Director | 02 May 2025, 16:01 |
| SNDX | Syndax Pharmaceuticals Inc | 10 Feb 2025 | 1 | -$71,597 | 4 | President, Head of R&D | 12 Feb 2025, 17:13 |
| SNDX | Syndax Pharmaceuticals Inc | 05 Feb 2025 | 3 | +$1,618,825 | 4 | President, Head of R&D | 07 Feb 2025, 16:45 |
| ZYME | Zymeworks Inc. | 10 Dec 2024 | 1 | $0 | 4 | Director | 12 Dec 2024, 17:49 |
| ZYME | Zymeworks Inc. | 02 Apr 2024 | 1 | $0 | 4 | Director | 02 Apr 2024, 21:54 |
| ZYME | Zymeworks Inc. | 02 Apr 2024 | 0 | $0 | 3 | Director | 02 Apr 2024, 21:52 |
| SNDX | Syndax Pharmaceuticals Inc | 07 Feb 2024 | 3 | +$1,545,675 | 4 | President, Head of R&D | 09 Feb 2024, 16:05 |
| SNDX | Syndax Pharmaceuticals Inc | 10 Apr 2023 | 1 | +$4,837,500 | 4 | President, Head of R&D | 12 Apr 2023, 16:02 |
| SNDX | Syndax Pharmaceuticals Inc | 10 Apr 2023 | 0 | $0 | 3 | President, Head of R&D | 12 Apr 2023, 16:01 |